McKay, R. R., Abida, W., Attard, G., Hadaschik, B. A., Kobayashi, T., Shore, N. D., Xing, N., Aregay, M., Donegan, S. E., Ost, P. (2026). Phase III, randomized, double-blind, placebo-controlled study of adjuvant saruparib (AZD5305) in patients with BRCAm localized high-risk prostate cancer who are receiving radiotherapy and androgen deprivation therapy (EvoPAR-Prostate02).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps412